KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Cash & Equivalents (2016 - 2025)

Pfizer (PFE) has disclosed Cash & Equivalents for 17 consecutive years, with $1.3 billion as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 22.99% to $1.3 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $1.3 billion, a 22.99% increase, with the full-year FY2024 number at $1.0 billion, down 63.44% from a year prior.
  • Cash & Equivalents was $1.3 billion for Q3 2025 at Pfizer, down from $1.6 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $3.1 billion in Q4 2023 to a low of $416.0 million in Q4 2022.
  • A 5-year average of $1.7 billion and a median of $1.8 billion in 2021 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 78.6% in 2022, then skyrocketed 585.82% in 2023.
  • Pfizer's Cash & Equivalents stood at $1.9 billion in 2021, then plummeted by 78.6% to $416.0 million in 2022, then surged by 585.82% to $2.9 billion in 2023, then tumbled by 63.44% to $1.0 billion in 2024, then grew by 28.76% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Cash & Equivalents are $1.3 billion (Q3 2025), $1.6 billion (Q2 2025), and $1.4 billion (Q1 2025).